<DOC>
	<DOCNO>NCT00428909</DOCNO>
	<brief_summary>A non-randomized , open-label study investigate effect imatinib mesylate pharmacokinetics acetaminophen/paracetamol patient newly diagnose , previously untreated chronic myeloid leukemia chronic phase ( CML-CP )</brief_summary>
	<brief_title>Effect Imatinib Mesylate Pharmacokinetics Acetaminophen/Paracetamol Patients With Newly Diagnosed , Previously Untreated Chronic Myeloid Leukemia Chronic Phase ( CML-CP )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion criterion : Ability provide write informed consent prior participation study . Male female patient ≥ 18 ≤ 75 year age Patients CMLCP within 6 month diagnosis ( date initial diagnosis date first cytogenetic analysis ) . FISH analysis accept . Diagnosis CML chronic phase cytogenetic confirmation Philadelphia chromosome ( 9 ; 22 ) translocation presence BcrAbl Documented chronic phase CML define : &lt; 15 % blast peripheral blood bone marrow &lt; 30 % blast plus promyelocytes peripheral blood bone marrow &lt; 20 % basophils peripheral blood ≥ 100 x 109/L ( ≥ 100,000 /mm3 ) platelets No evidence extramedullary leukemic involvement , exception hepatosplenomegaly Adequate end organ function define : total bilirubin &lt; 1.5 x ULN SGOT SGPT &lt; 2.5 x UNL creatinine &lt; 1.5 x ULN Female patient childbearing potential must negative serum pregnancy test within 7 day initiation study drug Exclusion criterion : Patients late chronic phase , accelerated phase , blastic phase exclude Patients receive investigational agent Patients receive imatinib duration prior study entry Patient receive treatment CML prior study entry longer 2 week exception hydroxyurea and/or anagrelide Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention Patients : pregnant breast feed childbearing potential without negative pregnancy test prior baseline male female childbearing potential unwilling use barrier contraceptive precaution throughout trial Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Patient severe uncontrolled medical condition ( i.e. , uncontrolled diabetes , chronic renal disease ) Patient previously receive radiotherapy ≥ 25 % bone marrow Patient major surgery within 4 week prior study entry , recover prior major surgery Patients ECOG Performance Status Score ≥ 3 Patients International normalized ratio ( INR ) partial thromboplastin time ( PTT ) &gt; 1.5 x IULN , exception patient treatment oral anticoagulant Patients know positivity human immunodeficiency virus ( HIV ) baseline test HIV require Patients significant history noncompliance medical regimen inability grant reliable informed consent Patients identify sibling donor allogeneic bone marrow transplant elect first line treatment Patients chronic user acetaminophen medication contain acetaminophen . Patients receive acetaminophen medication contain acetaminophen within 72 hour prior study entry . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>STI571</keyword>
	<keyword>imatinib</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>acetaminophen</keyword>
</DOC>